NanOlogy enrolls first patient in phase 1/2 clinical trial of NanoDoce to treat bladder cancer
The Phase 1/2 dose-rising trial will evaluate the safety and preliminary efficacy of NanoDoce for patients with high-risk non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer